Top

CardioVascular and Interventional Radiology

Published in:

Open Access 12-07-2022 | Heparin | Review

Endovascular Stenting in Superior Vena Cava Syndrome: A Systematic Review and Meta-analysis

Authors: Eri Yin-Soe Aung, Maha Khan, Norman Williams, Usman Raja, Mohamad Hamady

Published in: CardioVascular and Interventional Radiology | Issue 9/2022

Abstract

Purpose

Endovascular stenting has been used to manage superior vena cava syndrome for several decades and has become standard firstline practice. This study aims to investigate the outcomes of endovascular stenting in the management of superior vena cava syndrome (SVCS).

Methods

MEDLINE, EMBASE and PUBMED online databases were searched, with studies involving more than ten adult patients included. Studies identified spanned 27 years, from 1993 to 2020. Meta-analyses were performed based on Clopper–Pearson estimation.

Results

Fifty-four studies were identified, for a total of 2249 patients, of which 2015 had malignant SVCS and 222 benign SVCS. Pooled technical success and clinical success rates were 96.8% (95% CI 96.0–97.5%) and 92.8% (95% CI 91.7–93.8%). Technical success and clinical success rates for studies investigating benign SVCS alone were identical at 88.8% (95% CI 83.0–93.1%). Pooled patency remained above 90% for the first year. Average complication and re-intervention rates were 5.78% (SD = 9.3182) and 9.11% (SD = 11.190).

Conclusions

This review confirms the effectiveness of endovascular stenting in managing SVCS. Further directions of research may include specific outcomes of endovascular stenting in benign SVCS, and the impact of procedural characteristics, such as the use of anticoagulation and type of stent used, on outcomes.

Level of Evidence

Level III, systematic review of retrospective cohort studies.

Friedman T, Quencer K, Kishore S, Winokur R, Madoff D. Malignant venous obstruction: superior vena cava syndrome and beyond. Semin Interv Radiol. 2017;34(04):398–408. https://doi.org/10.1055/s-0037-1608863.CrossRef

Cheng S. Superior vena cava syndrome. Cardiol Rev. 2009;17(1):16–23. https://doi.org/10.1097/crd.0b013e318188033c.CrossRefPubMed

Wilson L, Detterbeck F, Yahalom J. Superior vena cava syndrome with malignant causes. N Engl J Med. 2007;356(18):1862–9. https://doi.org/10.1056/nejmcp067190.CrossRefPubMed

Azizi A, Shafi I, Shah N, Rosenfield K, Schainfeld R, Sista A, Bashir R. Superior vena cava syndrome. JACC Cardiovasc Interv. 2020;13(24):2896–910. https://doi.org/10.1016/j.jcin.2020.08.038.CrossRefPubMed

Rice T, Rodriguez R, Light R. The superior vena cava syndrome. Medicine. 2006;85(1):37–42. https://doi.org/10.1097/01.md.0000198474.99876.f0.CrossRefPubMed

Deshwal H, Ghosh S, Magruder K, Bartholomew J, Montgomery J, Mehta A. A review of endovascular stenting for superior vena cava syndrome in fibrosing mediastinitis. Vasc Med. 2019;25(2):174–83. https://doi.org/10.1177/1358863x19884130.CrossRefPubMed

Sfyroeras G, Antonopoulos C, Mantas G, Moulakakis K, Kakisis J, Brountzos E, et al. A review of open and endovascular treatment of superior vena cava syndrome of benign aetiology. Eur J Vasc Endovasc Surg. 2017;53(2):238–54. https://doi.org/10.1016/j.ejvs.2016.11.013.CrossRefPubMed

Chee C, Bjarnason H, Prasad A. Superior vena cava syndrome: an increasingly frequent complication of cardiac procedures. Nat Clin Pract Cardiovasc Med. 2007;4(4):226–30. https://doi.org/10.1038/ncpcardio0850.CrossRefPubMed

Butty S, Johnson M, Stevens D. Superior vena cava rupture and cardiac tamponade complicating the endovascular treatment of malignant superior vena cava syndrome: a case report and literature review. Semin Interv Radiol. 2015;32(04):439–44. https://doi.org/10.1055/s-0035-1564795.CrossRef

10.

Rizvi A, Kalra M, Bjarnason H, Bower T, Schleck C, Gloviczki P. Benign superior vena cava syndrome: stenting is now the first line of treatment. J Vasc Surg. 2008;47(2):372–80. https://doi.org/10.1016/j.jvs.2007.09.071.CrossRefPubMed

11.

Rachapalli V, Boucher L. Superior vena cava syndrome: role of the interventionalist. Can Assoc Radiol J. 2014;65(2):168–76. https://doi.org/10.1016/j.carj.2012.09.003.CrossRefPubMed

12.

Nicholson A, Ettles D, Arnold A, Greenstone M, Dyet J. Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy. J Vasc Interv Radiol. 1997;8(5):781–8. https://doi.org/10.1016/s1051-0443(97)70660-2.CrossRefPubMed

13.

McInnes MDF, Moher D, Thombs BD, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319:388–96.CrossRef

14.

Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (2021). Retrieved 17 May 2021

15.

Gaines P, Belli A, Anderson P, McBride K, Hemingway A. Superior vena caval obstruction managed by the gianturco Z stent. Clin Radiol. 1994;49(3):202–8. https://doi.org/10.1016/s0009-9260(05)81778-7.CrossRefPubMed

16.

Niu S, Xu Y, Cheng L, Cao C. Stent insertion for malignant superior vena cava syndrome: effectiveness and long-term outcome. Radiol Med (Torino). 2017;122(8):633–8. https://doi.org/10.1007/s11547-017-0767-1.CrossRef

17.

Wei S, Liu J, Li X, Song Z, Dong M, Zhao H, et al. A retrospective stenting study on superior vena cava syndrome caused by lung cancer. Thorac Cancer. 2020;11(7):1835–9. https://doi.org/10.1111/1759-7714.13461.CrossRefPubMedPubMedCentral

18.

Oudkerk M, Kuijpers T, Schmitz P, Loosveld O, de Wit R. Self-expanding metal stents for palliative treatment of superior vena caval syndrome. Cardiovasc Interv Radiol. 1996;19(3):146–51. https://doi.org/10.1007/s002709900032.CrossRef

19.

Lanciego C, Chacón J, Julián A, Andrade J, López L, Martinez B, et al. Stenting as first option for endovascular treatment of malignant superior vena cava syndrome. Am J Roentgenol. 2001;177(3):585–93. https://doi.org/10.2214/ajr.177.3.1770585.CrossRef

20.

Bierdrager E, Lampmann LE, Lohle PN, Schoemaker CM, Schijen JH, Palmen FM, van der Heul C. Endovascular stenting in neoplastic superior vena cava syndrome prior to chemotherapy or radiotherapy. Neth J Med. 2005;63(1):20–3.PubMed

21.

Lanciego C, Pangua C, Chacón J, Velasco J, Boy R, Viana A, et al. Endovascular stenting as the first step in the overall management of malignant superior vena cava syndrome. Am J Roentgenol. 2009;193(2):549–58. https://doi.org/10.2214/ajr.08.1904.CrossRef

22.

Majumdar S, Shoela R, Kim D, Ramaswamy R, Mani N, Salter A, Akinwande O. Endovascular management of SVC syndrome due to fibrosing mediastinitis—a feasibility and safety analysis. Vasc Endovasc Surg. 2018;52(3):202–6. https://doi.org/10.1177/1538574418757401.CrossRef

23.

Maleux G, Gillardin P, Fieuws S, Heye S, Vaninbroukx J, Nackaerts K. Large-bore nitinol stents for malignant superior vena cava syndrome: factors influencing outcome. Am J Roentgenol. 2013;201(3):667–74. https://doi.org/10.2214/ajr.12.9582.CrossRef

24.

Cho Y, Gwon D, Ko G, Ko H, Kim J, Shin J, et al. Covered stent placement for the treatment of malignant superior vena cava syndrome: is unilateral covered stenting safe and effective? Korean J Radiol. 2014;15(1):87. https://doi.org/10.3348/kjr.2014.15.1.87.CrossRefPubMedPubMedCentral

25.

Gwon D, Ko G, Kim J, Shin J, Yoon H, Sung K. Malignant superior vena cava syndrome: a comparative cohort study of treatment with covered stents versus uncovered stents. Radiology. 2013;266(3):979–87. https://doi.org/10.1148/radiol.12120517.CrossRefPubMed

26.

Haddad M, Simmons B, McPhail I, Kalra M, Neisen M, Johnson M, et al. Comparison of covered versus uncovered stents for benign superior vena cava (SVC) obstruction. Cardiovasc Interv Radiol. 2018;41(5):712–7. https://doi.org/10.1007/s00270-018-1906-3.CrossRef

27.

Wang Z, Li C, Li J, Wu W, Li Y, Shi J. Covered versus uncovered stent insertion for malignant superior vena cava obstruction. Minim Invasive Ther Allied Technol. 2019;29(6):353–8. https://doi.org/10.1080/13645706.2019.1653925.CrossRefPubMed

28.

Dyet J, Nicholson A, Cook A. The use of the wallstent endovascular prosthesis in the treatment of malignant obstruction of the superior vena cava. Clin Radiol. 1993;48(6):381–5. https://doi.org/10.1016/s0009-9260(05)81105-5.CrossRefPubMed

29.

Sasano S, Onuki T, Mae M, Oyama K, Sakuraba M, Nitta S. Wallstent endovascular prosthesis for the treatment of superior vena cava syndrome. Jpn J Thorac Cardiovasc Surg. 2001;49(3):165–70. https://doi.org/10.1007/bf02913595.CrossRefPubMed

30.

Urruticoechea A. Treatment of malignant superior vena cava syndrome by endovascular stent insertion experience on 52 patients with lung cancer. Lung Cancer. 2004;43(2):209–14. https://doi.org/10.1016/s0169-5002(03)00361-1.CrossRefPubMed

31.

Nagata T, Makutani S, Uchida H, Kichikawa K, Maeda M, Yoshioka T, et al. Follow-up results of 71 patients undergoing metallic stent placement for the treatment of a malignant obstruction of the superior vena cava. Cardiovasc Interv Radiol. 2007;30(5):959–67. https://doi.org/10.1007/s00270-007-9088-4.CrossRef

32.

Gross C, Krämer J, Waigand J, Uhlich F, Schröder G, Thalhammer C, et al. Stent implantation in patients with superior vena cava syndrome. Am J Roentgenol. 1997;169(2):429–32. https://doi.org/10.2214/ajr.169.2.9242747.CrossRef

33.

Qanadli S, El Hajjam M, Mignon F, de Kerviler E, Rocha P, Barré O, et al. Subacute and chronic benign superior vena cava obstructions: endovascular treatment with self-expanding metallic stents. Am J Roentgenol. 1999;173(1):159–64. https://doi.org/10.2214/ajr.173.1.10397119.CrossRef

34.

Cho T, Janho K, Mohan I. The role of stenting the superior vena cava syndrome in patients with malignant disease. Angiology. 2010;62(3):248–52. https://doi.org/10.1177/0003319710382772.CrossRefPubMed

35.

Crowe M, Davies C, Gaines P. Percutaneous management of superior vena cava occlusions. Cardiovasc Interv Radiol. 1995;18(6):367–72. https://doi.org/10.1007/bf00338303.CrossRef

36.

Tanigawa N, Sawada S, Mishima K, Okuda Y, Mizukawa K, Ohmura N, et al. Clinical outcome of stenting in superior vena cava syndrome associated with malignant tumors. Acta Radiol. 1998;39(6):669–74. https://doi.org/10.3109/02841859809175494.CrossRefPubMed

37.

Thony F, Moro D, Witmeyer P, Angiolini S, Brambilla C, Coulomb M, Ferretti G. Endovascular treatment of superior vena cava obstruction in patients with malignancies. Eur Radiol. 1999;9(5):965–71. https://doi.org/10.1007/s003300050777.CrossRefPubMed

38.

Smayra T, Otal P, Chabbert V, Chemla P, Romero M, Joffre F, Rousseau H. Long-term results of endovascular stent placement in the superior caval venous system. Cardiovasc Interv Radiol. 2001;24(6):388–94. https://doi.org/10.1007/s00270-001-0055-1.CrossRef

39.

Fagedet D, Thony F, Timsit J, Rodiere M, Monnin-Bares V, Ferretti G, et al. Endovascular treatment of malignant superior vena cava syndrome: results and predictive factors of clinical efficacy. Cardiovasc Interv Radiol. 2011;36(1):140–9. https://doi.org/10.1007/s00270-011-0310-z.CrossRef

40.

Sobrinho G, Aguiar P. Stent placement for the treatment of malignant superior vena cava syndrome—a single-center series of 56 patients. Arch Bronconeumol (Engl Ed). 2014;50(4):135–40. https://doi.org/10.1016/j.arbr.2014.03.001.CrossRef

41.

Leung S, Sung T, Wan A, Leung K, Kan W. Endovascular stenting in the management of malignant superior vena cava obstruction: comparing safety, effectiveness, and outcomes between primary stenting and salvage stenting. Hong Kong Med J. 2015. https://doi.org/10.12809/hkmj144363.CrossRefPubMed

42.

Ren J, Cao C, Fu Y, Du H. Double stent insertion for combined malignant airway and superior vena cava obstruction. Medicine. 2019;98(21):e15777. https://doi.org/10.1097/md.0000000000015777.CrossRefPubMedPubMedCentral

43.

Duvnjak S, Andersen P. Palliative treatment of superior vena cava syndrome with nitinol stents. Int J Angiol. 2014;23(04):255–62. https://doi.org/10.1055/s-0034-1383432.CrossRefPubMedPubMedCentral

44.

Andersen P, Midtgaard A, Brenoe A, Elle B, Duvnjak S. A new nitinol stent for use in superior vena cava syndrome. Initial clinical experience. J Cardiovasc Surg. 2015;56(6):877–81.

45.

Sacks D, McClenny T, Cardella J, Lewis C. Society of interventional radiology clinical practice guidelines. J Vasc Interv Radiol. 2003;14(9):S199–202. https://doi.org/10.1097/01.rvi.0000094584.83406.3e.CrossRefPubMed

46.

Anton S, Oechtering T, Stahlberg E, Jacob F, Kleemann M, Barkhausen J, Goltz J. Endovascular stent-based revascularization of malignant superior vena cava syndrome with concomitant implantation of a port device using a dual venous approach. Support Care Cancer. 2017;26(6):1881–8. https://doi.org/10.1007/s00520-017-3997-9.CrossRefPubMed

47.

Mokry T, Bellemann N, Sommer C, Heussel C, Bozorgmehr F, Gnutzmann D, et al. Retrospective study in 23 patients of the self-expanding sinus-XL stent for treatment of malignant superior vena cava obstruction caused by non-small cell lung cancer. J Vasc Interv Radiol. 2015;26(3):357–65. https://doi.org/10.1016/j.jvir.2014.11.019.CrossRefPubMed

48.

Kishi K, Sonomura T, Mitsuzane K, Nishida N, Yang R, Sato M, et al. Self-expandable metallic stent therapy for superior vena cava syndrome: clinical observations. Radiology. 1993;189(2):531–5. https://doi.org/10.1148/radiology.189.2.8210386.CrossRefPubMed

49.

Dinkel H, Mettke B, Schmid F, Baumgartner I, Triller J, Do D. Endovascular treatment of malignant superior vena cava syndrome: is bilateral wallstent placement superior to unilateral placement? J Endovasc Ther. 2003;10(4):788–97. https://doi.org/10.1177/152660280301000416.CrossRefPubMed

50.

Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse quality assurance document and standards for classification of complications: the CIRSE classification system. Cardiovasc Intervent Radiol. 2017;40(8):1141–6. https://doi.org/10.1007/s00270-017-1703-4.CrossRefPubMed

51.

Stock K, Jacob A, Proske M, Bolliger C, Rochlitz C, Steinbrich W. Treatment of malignant obstruction of the superior vena cava with the self-expanding Wallstent. Thorax. 1995;50(11):1151–6. https://doi.org/10.1136/thx.50.11.1151.CrossRefPubMedPubMedCentral

52.

Barshes N, Annambhotla S, El Sayed H, Huynh T, Kougias P, Dardik A, Lin P. Percutaneous stenting of superior vena cava syndrome: treatment outcome in patients with benign and malignant etiology. Vascular. 2007;15(5):314–21. https://doi.org/10.2310/6670.2007.00067.CrossRefPubMed

53.

de Gregorio Ariza M, Gamboa P, Gimeno M, Alfonso E, Mainar A, Medrano J, et al. Percutaneous treatment of superior vena cava syndrome using metallic stents. Eur Radiol. 2003;13(4):853–62. https://doi.org/10.1007/s00330-002-1489-9.CrossRefPubMed

54.

Mónaco R. Use of self-expanding vascular endoprostheses in superior vena cava syndrome. Eur J Cardiothorac Surg. 2003;24(2):208–11. https://doi.org/10.1016/s1010-7940(03)00293-8.CrossRef

55.

Ratzon R, Tamir S, Friehmann T, Livneh N, Dudnik E, Rozental A, et al. Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome. J Thromb Thrombol. 2018;47(1):121–8. https://doi.org/10.1007/s11239-018-1747-6.CrossRef

56.

Haddad M, Thompson S, McPhail I, Bendel E, Kalra M, Stockland A, et al. Is long-term anticoagulation required after stent placement for benign superior vena cava syndrome? J Vasc Interv Radiol. 2018;29(12):1741–7. https://doi.org/10.1016/j.jvir.2018.07.020.CrossRefPubMed

57.

Hennequin L, Fade O, Fays J, Bic J, Jaafar S, Bertal A, et al. Superior vena cava stent placement: results with the wallstent endoprosthesis. Radiology. 1995;196(2):353–61. https://doi.org/10.1148/radiology.196.2.7617844.CrossRefPubMed

58.

Shah R, Sabanathan S, Lowe R, Mearns A. Stenting in malignant obstruction of superior vena cava. J Thorac Cardiovasc Surg. 1996;112(2):335–40. https://doi.org/10.1016/s0022-5223(96)70259-3. CrossRefPubMed

59.

Marcy P, Magné N, Bentolila F, Drouillard J, Bruneton J, Descamps B. Superior vena cava obstruction: is stenting necessary? Support Care Cancer. 2001;9(2):103–7. https://doi.org/10.1007/s005200000173.CrossRefPubMed

60.

Miller J, McBride K, Little F, Price A. Malignant superior vena cava obstruction: stent placement via the subclavian route. Cardiovasc Interv Radiol. 2000;23(2):155–8. https://doi.org/10.1007/s002709910033.CrossRef

61.

Chatziioannou A, Alexopoulos T, Mourikis D, Dardoufas K, Katsenis K, Lazarou S, et al. Stent therapy for malignant superior vena cava syndrome. Eur J Radiol. 2003;47(3):247–50. https://doi.org/10.1016/s0720-048x(02)00207-3.CrossRefPubMed

62.

Courtheoux P, Alkofer B, Al Refaï M, Gervais R, Le Rochais J, Icard P. Stent placement in superior vena cava syndrome. Ann Thorac Surg. 2003;75(1):158–61. https://doi.org/10.1016/s0003-4975(02)04293-5.CrossRefPubMed

63.

Kim Y, Kim K, Ko Y, Park C, Lim S, Kim Y, et al. Endovascular stenting as a first choice for the palliation of superior vena cava syndrome. J Korean Med Sci. 2004;19(4):519. https://doi.org/10.3346/jkms.2004.19.4.519.CrossRefPubMedPubMedCentral

64.

Sheikh M, Fernandez B, Gray B, Graham L, Carman T. Endovascular stenting of nonmalignant superior vena cava syndrome. Catheter Cardiovasc Interv. 2005;65(3):405–11. https://doi.org/10.1002/ccd.20458.CrossRefPubMed

65.

Breault S, Doenz F, Jouannic A, Qanadli S. Percutaneous endovascular management of chronic superior vena cava syndrome of benign causes: long-term follow-up. Eur Radiol. 2016;27(1):97–104. https://doi.org/10.1007/s00330-016-4354-y.CrossRefPubMed

66.

Miazga M, Jargiełło T, Drelich-Zbroja A, Karska K, Pyra K, Sojka M, et al. Endovascular treatment for superior vena cava obstruction. Postępy Nauk Medycznych. 2015;28(2):124–8. https://doi.org/10.5604/08606196.1150855.CrossRef

67.

Calsina Juscafresa L, Gil Bazo I, Grochowicz L, Páramo Alfaro M, López-Picazo González J, Moreno Jiménez M, Bilbao Jaureguizar J. Endovascular treatment of malignant superior vena cava syndrome secondary to lung cancer. Hosp Pract. 2017;45(3):70–5. https://doi.org/10.1080/21548331.2017.1342507.CrossRef

68.

Kuo T, Chen P, Shih C, Chen I. Endovascular stenting for end-stage lung cancer patients with superior vena cava syndrome post first-line treatments—a single-center experience and literature review. J Chin Med Assoc. 2017;80(8):482–6. https://doi.org/10.1016/j.jcma.2017.04.005.CrossRefPubMed

69.

Büstgens F, Loose R, Ficker J, Wucherer M, Uder M, Adamus R. Stent Implantation for Superior Vena Cava Syndrome of Malignant Cause. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 2017;189(05):423–430. https://doi.org/10.1055/s-0042-122147.CrossRef

70.

Wilson LD, Detterbeck FC, Yahalom J. Superior Vena Cava Syndrome with Malignant Causes. N Engl J Med. 2007;356(18):1862–1869. https://doi.org/10.1056/NEJMcp067190.CrossRefPubMed

71.

Massara M, De Caridi G, Alberti A, Volpe P, Spinelli F. Symptomatic superior vena cava syndrome in hemodialysis patients: mid-term results of primary stenting. Semin Vasc Surg. 2016;29(4):186–191. https://doi.org/10.1053/j.semvascsurg.2017.05.001.CrossRefPubMed

72.

Karakhanian WK, Karakhanian WZ, Belczak SQ. Superior vena cava syndrome: endovascular management. J Vasc Bras. 2019;18:e20180062. https://doi.org/10.1590/1677-5449.180062.CrossRefPubMedPubMedCentral

Title: Endovascular Stenting in Superior Vena Cava Syndrome: A Systematic Review and Meta-analysis
Authors: Eri Yin-Soe Aung
Maha Khan
Norman Williams
Usman Raja
Mohamad Hamady
Publication date: 12-07-2022
Publisher: Springer US
Keywords: Heparin
Phlebography
CT of the Thorax
Published in: CardioVascular and Interventional Radiology / Issue 9/2022
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-022-03178-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Endovascular Stenting in Superior Vena Cava Syndrome: A Systematic Review and Meta-analysis

Abstract

Purpose

Methods

Results

Conclusions

Level of Evidence

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Level of Evidence

Please log in to get access to this content

Other articles of this Issue 9/2022

Comparison of Restenosis Risk in Single-Layer versus Dual-Layer Carotid Stents: A Duplex Ultrasound Evaluation

Long-Term Outcome of Prostatic Artery Embolization for Patients with Benign Prostatic Hyperplasia: Single-Centre Retrospective Study in 1072 Patients Over a 10-Year Period

CVIR Editors’ Medal 2022

Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

Degenerated, Pouch-Shaped, Intermittently Protruding Median Lobe Causing Early Symptomatic Recurrence After Prostatic Artery Embolization

Hemorrhoid Embolization: Is it Time for Standardization?